Lixiao Hao1, Xiaoni Wang2, Ling Zhang3, Yue Xing4,5, Qihao Guo6, Xiaochen Hu7, Bin Mu2, Yili Chen8, Guanqun Chen2, Jing Cao9, Xiaodong Zhi10, Jiaojiao Liu11, Xuanyu Li2, Liu Yang2, Jiachen Li2, Wenying Du2, Yu Sun2, Ting Wang1, Zhen Liu12, Zheng Liu3, Xuexue Zhao1, Hongyan Li13, Yang Yu14, Xue Wang15, Jianguo Jia16, Ying Han2,17,18,19,20. 1. Department of General Practice, School of General Practice and Continuing Education of Capital Medical University, Beijing, China. 2. Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China. 3. Department of Epidemiology and Health Statistics, School of Public Health of Capital Medical University, Beijing, China. 4. Radiological Sciences, Division of Clinical Neuroscience, Queen's Medical Centre, University of Nottingham, Nottingham, UK. 5. Sir Peter Mansfield Imaging Centre, School of Medicine, University of Nottingham, Nottingham, UK. 6. Department of Neurology, Huashan Hospital of Fudan University, Shanghai, China. 7. Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany. 8. Department of Neurology, Dali People's Hospital, Yunnan, China. 9. Department of Neurology, Hong Xinglong Center Hospital, Heilongjiang, China. 10. Department of Neurology, Lanzhou General Hospital of Lanzhou Military Command, Gansu, China. 11. Department of Radiology, Youan Hospital of Capital Medical University, Beijing, China. 12. Department of General Practice, XuanWu Hospital of Capital Medical University, Beijing, China. 13. Department of Neurology, Civil Aviation General Hospital, Beijing, China. 14. Department of Neurology, Hongqi Hospital of Mudanjiang Medical University, Heilongjiang, China. 15. Department of Library, XuanWu Hospital of Capital Medical University, Beijing, China. 16. Department of General Surgery, XuanWu Hospital of Capital Medical University, Beijing, China. 17. Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China. 18. Beijing Institute of Geriatrics, Beijing, China. 19. National Clinical Research Center for Geriatric Disorders, Beijing, China. 20. PKU Care Rehabilitation Hospital, Beijing, China.
Abstract
BACKGROUND: Substantial studies have reported the prevalence and the affecting factors of subjective cognitive decline (SCD). The complaints screening scale has also been used for probing. However, little is known in China. OBJECTIVE: To investigate the prevalence and risk factors of SCD, and explore an SCD complaints screening scale in China. METHODS: Stratified cluster random sampling was conducted. 2,689 residents aged 60-80 years completed questionnaire 1. 814 residents were included for clinical and neuropsychological evaluations. Two standards were used to make the diagnosis of mild cognitive impairment (MCI) and SCD, and a preliminary screening rate comparison was carried out. Finally, we assessed the risk factors of SCD and the correlation between the SCD-questionnaire 9 (SCD-Q9) and the Auditory Verbal Learning Test-Long Delay Free Recall (AVLT-LR). RESULTS: 1) Standard 1 (ADNI2): the prevalence of SCD was 18.8% (95% CI = 14.7-22.9%) and zero conformed to six criteria (SCD plus). 2) Standard 2 (Jak/Bondi): the prevalence of SCD was 14.4% (95% CI = 10.7-18.1%). 3) Standard 1 had a relatively higher "false" positive rate, whereas Standard 2 had higher "false" negative rate. 4) Age, low education, fewer close friends, and daily drinking were independent risk factors for SCD progressing to MCI. 5) Total points of SCD-Q9 were negatively correlated to the value of AVLT-LR. CONCLUSIONS: The prevalence of SCD is high in the ShunYi District in Beijing, China. Age, low education, less social support, and daily drinking are independent risk factors. The brief SCD-Q9 can be used as a reference.
BACKGROUND: Substantial studies have reported the prevalence and the affecting factors of subjective cognitive decline (SCD). The complaints screening scale has also been used for probing. However, little is known in China. OBJECTIVE: To investigate the prevalence and risk factors of SCD, and explore an SCD complaints screening scale in China. METHODS: Stratified cluster random sampling was conducted. 2,689 residents aged 60-80 years completed questionnaire 1. 814 residents were included for clinical and neuropsychological evaluations. Two standards were used to make the diagnosis of mild cognitive impairment (MCI) and SCD, and a preliminary screening rate comparison was carried out. Finally, we assessed the risk factors of SCD and the correlation between the SCD-questionnaire 9 (SCD-Q9) and the Auditory Verbal Learning Test-Long Delay Free Recall (AVLT-LR). RESULTS: 1) Standard 1 (ADNI2): the prevalence of SCD was 18.8% (95% CI = 14.7-22.9%) and zero conformed to six criteria (SCD plus). 2) Standard 2 (Jak/Bondi): the prevalence of SCD was 14.4% (95% CI = 10.7-18.1%). 3) Standard 1 had a relatively higher "false" positive rate, whereas Standard 2 had higher "false" negative rate. 4) Age, low education, fewer close friends, and daily drinking were independent risk factors for SCD progressing to MCI. 5) Total points of SCD-Q9 were negatively correlated to the value of AVLT-LR. CONCLUSIONS: The prevalence of SCD is high in the ShunYi District in Beijing, China. Age, low education, less social support, and daily drinking are independent risk factors. The brief SCD-Q9 can be used as a reference.
Authors: Susanne Röhr; Alexander Pabst; Steffi G Riedel-Heller; Frank Jessen; Yuda Turana; Yvonne S Handajani; Carol Brayne; Fiona E Matthews; Blossom C M Stephan; Richard B Lipton; Mindy J Katz; Cuiling Wang; Maëlenn Guerchet; Pierre-Marie Preux; Pascal Mbelesso; Karen Ritchie; Marie-Laure Ancelin; Isabelle Carrière; Antonio Guaita; Annalisa Davin; Roberta Vaccaro; Ki Woong Kim; Ji Won Han; Seung Wan Suh; Suzana Shahar; Normah C Din; Divya Vanoh; Martin van Boxtel; Sebastian Köhler; Mary Ganguli; Erin P Jacobsen; Beth E Snitz; Kaarin J Anstey; Nicolas Cherbuin; Shuzo Kumagai; Sanmei Chen; Kenji Narazaki; Tze Pin Ng; Qi Gao; Xinyi Gwee; Henry Brodaty; Nicole A Kochan; Julian Trollor; Antonio Lobo; Raúl López-Antón; Javier Santabárbara; John D Crawford; Darren M Lipnicki; Perminder S Sachdev Journal: Alzheimers Res Ther Date: 2020-12-18 Impact factor: 6.982